Stock comparison
argenx SE
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ARGX
argenx SE
Market cap
$50.29B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ARGX | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 77B | LMAT |
| Benjamin Graham | 74D | 89A | LMAT |
| Philip Fisher | 80C | 81C | LMAT |
| Peter Lynch | 71B | 67B | ARGX |
| Joel Greenblatt | 57C | 56D | ARGX |
| Charlie Munger | 59D | 68D | LMAT |
| Terry Smith | 53D | 69D | LMAT |
Side-by-side metrics
| Metric | ARGX | LMAT |
|---|---|---|
| Market cap | $50.29B | $2.32B |
| P/E (TTM) | 44.1x | 37.1x |
| EV/EBIT | 44.4x | 36.6x |
| ROIC (TTM) | 11.74% | 9.43% |
| Gross margin | 89.0% | 72.39% |
| Net margin | 33.42% | 24.35% |
| Revenue CAGR 5y | 70.0% | 12.75% |
| EPS CAGR 5y | 42.58% | 19.04% |
| Debt / Equity | 0.0x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ARGX leads on
- Debt / Equity0.0xvs 0.5x+98%
- Market cap$50.29Bvs $2.32B+95%
- Revenue CAGR 5y70.0%vs 12.75%+82%
- EPS CAGR 5y42.58%vs 19.04%+55%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EV/EBIT36.6xvs 44.4x+17%
- P/E (TTM)37.1xvs 44.1x+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.